Targeted treatment of papillary craniopharyngiomas harboring BRAF V600E mutations

Papillary craniopharyngiomas (PCPs) are characterized by the presence of BRAF V600E mutations, which are emerging as a useful guide for diagnosis and treatment decision making. The ongoing multicenter phase 2 Alliance A071601 trial is evaluating the efficacy of BRAF and mitogen-activated protein kin...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Cancer
Autores principales: Juratli, Tareq A., Jones, Pamela S., Wang, Nancy, Subramanian, Megha, Aylwin, Simon J.B., Odia, Yazmin, Rostami, Elham, Gudjonsson, Olafur, Shaw, Brian L., Cahill, Daniel P., Galanis, Evanthia, Barker, Fred G., Santagata, Sandro, Brastianos, Priscilla K.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2019
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC7032527/
https://ncbi.nlm.nih.gov/pubmed/31314136
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.32197
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares